Additionally, we have demonstrated that reducing the transcript levels of Gli3/GLI3 levels in both of these contexts does not alter disease progression or spheroid size respectively, suggesting it is not required for ARPKD. The gene discussed is GLI3; the disease is autosomal recessive polycystic kidney disease.